UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 13, 2007
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of I	Registrant as Specified in	n its Charter)	
DELAWARE	1-11353	13-3757370	
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)	
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127	
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area co	de)
Check the appropriate box below if the Form 8-K filing is intende ollowing provisions: Written communications pursuant to Rule 425 under the Secu Soliciting material pursuant to Rule 14a-12 under the Exchang Pre-commencement communications pursuant to Rule 14d-2(Pre-commencement communications pursuant to Rule 13e-4(urities Act (17 CFR 230. ge Act (17 CFR 240.14a (b) under the Exchange	425) a-12) Act (17 CFR 240.14d-2(b))	of the
TEM 7.01. Regulation FD Disclosure			
On November 13, 2007, Laboratory Corporation of America [®] Ho Officer and William B. (Brad) Hayes, Executive Vice President ar Healthcare Conference in Phoenix, AZ. LabCorp's presentation i Fime).	nd Chief Financial Offic	er, are scheduled to speak at the Credit Suisse 20	007 Globa
Exhibits			
99.1 Press Release dated November 13, 2007			

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

Date: November 13, 2007

By: /s/Bradford T. Smith

Bradford T. Smith, Executive Vice President and Secretary

Laboratory Corporation of America® Holdings 358 South Main Street Burlington, NC 27215 Telephone:(336) 584-5171

FOR IMMEDIATE RELEASE

Investor/Media Contact: Eric Lindblom - 336-436-6739

Shareholder Direct: (800)LAB-0401 Company Information: www.labcorp.com

LABCORP IS SCHEDULED TO PRESENT AT THE CREDIT SUISSE 2007 GLOBAL HEALTHCARE CONFERENCE

Burlington, NC, November 13, 2007 — Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) today announced that David P. King, Chief Executive Officer and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Credit Suisse 2007 Global Healthcare Conference in Phoenix, AZ. LabCorp's presentation is planned for Thursday, November 15, 2007 at 10:30 a.m. (Mountain Standard Time).

A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay.

About LabCorp®

Laboratory Corporation of America[®] Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$3.6 billion in 2006, over 25,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our Web site at: www.labcorp.com.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2006, and subsequent SEC filings.